Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 3, 2016, Pages 259-270

  Schmidt, C ^a   Ahmad, T ^b   Tulassay, Z ^c   Baumgart, D C ^d,h   Bokemeyer, B ^e   Howaldt, S ^f   Stallmach, A ^a   Buning C ^g   Bokemeyer, Bernd ^h   Büning, Carsten ^h   Helwig, Ulf ^h   Howaldt, Stefanie ^h   Hüppe, Dietrich ^h   Krummenerl, Annette ^h   Krummenerl, Thomas ^h   Kühbacher, Tanja ^h   Landry, Wilfried ^h   Lügering, Andreas ^h   Maaser, Christian ^h   Mroß, Michael ^h   Seidler, Ursula ^h   Stein, Jürgen ^h   Teich, Niels ^h   Horvath, Gabor ^h   Kristóf, Tünde ^h   László, András ^h   Molnár, Tamás ^h   Salamon, Ágnes ^h   Vincze, Áron ^h   Krayenbuehl, Pierre ^h   Ahmad, Tariq ^h   Beales, Ian ^h   Brookes, Matthew ^h   Campbell, Simon ^h   Cummings, Fraser ^h   Ede, Ronald ^h   Elphick, David ^h   Ireland, Alan ^h   Kejariwal, Deepak ^h   Li, Andy ^h   Mansfield, John ^h   more..

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d HUMBOLDT UNIVERSITY   (Germany)

^e KLINIKUM MINDEN   (Germany)

^f Hamburg Institute of Ophthalmology   (Germany)

^g Waldfriede Hospital   (Germany)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; FERRIC MALTOL; FERRITIN; HEMOGLOBIN; INFLIXIMAB; MESALAZINE; PLACEBO; PREDNISOLONE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ALLERGY; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLUENZA; INTENTION TO TREAT ANALYSIS; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; VOMITING;

EID: 84977517134     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13665     Document Type: Article

References (41)

1. Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2013; 6: 61–70.
2. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185–92.
3. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211–22.
4. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599–610.
5. Gomollon F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009; 15: 4659–65.
6. Gasche C, Beguin Y, de Silva AD, et al. IBD and anemia. In: Gasche C, ed. Anemia in Inflammatory Bowel Diseases. Bremen, London, Boston: UNI-MED Verlag AG, 2008; 15–53.
7. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4: 63–101.
8. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123–30.
9. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health 2005; 8: 629–38.
10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011–23.
11. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545–53.
12. Blumenstein I, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Stein J. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis 2014; 8: 1308–14.
13. Gasche C, Beguin Y, de Silva AD. Anemia in Inflammatory Bowel Diseases. Bremen, London, Boston: UNI-MED Verlag AG, 2008.
14. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulphate supplementation causes significant gastrointestinal side effects in adults: a systematic review and meta-analysis. PLoS ONE 2015; 10: e0117383.
15. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991–1030.
16. D'Arcy PF, Howard EM. The acute toxicity of ferrous salts administered to dogs by mouth. J Pathol Bacteriol 1962; 83: 65–72.
17. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846–53 e1–2.
18. European Medicines Agency (EMA). New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. 13 September 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000435/human_med_001171.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 (accessed 22 April 2016).
19. Gomollon F, Chowers Y, Danese S, et al. Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. Aliment Pharmacol Ther 2014; 39: 743–4.
20. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med 2007; 357: 93–4.
21. Barrand MA, Callingham BA, Dobbin P, Hider RC. Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat. Br J Pharmacol 1991; 102: 723–9.
22. Kelsey SM, Hider RC, Bloor JR, Blake DR, Gutteridge CN, Newland AC. Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test. J Clin Pharm Ther 1991; 16: 117–22.
23. Kelsey SM, Blake DR, Hider RC, Gutteridge CN, Newland AC. Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects. Clin Lab Haematol 1989; 11: 287–8.
24. Barrand MA, Callingham BA. Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat. Br J Pharmacol 1991; 102: 408–14.
25. Levey JA, Barrand MA, Callingham BA, Hider RC. Characteristics of iron(III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol. Biochem Pharmacol 1988; 37: 2051–7.
26. Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015; 21: 579–88.
27. World Health Organisation (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. In: Maria de Regil, L, ed. Vitamin and Mineral Nutrition Information System (WHO/NMH/NHD/MNM/11.1). Geneva: World Health Organization, 2011; 1–4.
28. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83.
29. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29–32.
30. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44.
31. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2015; 387: 907–16.
32. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104: 1460–7.
33. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010; 60: 399–412.
34. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182–92.
35. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503–9.
36. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39: 454–8.
37. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058–65.
38. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Ann Gastroenterol 2013; 26: 104–13.
39. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44: 838–45.
40. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485–91.
41. Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 1998; 12: 845–8.